Study links clot-buster, angioplasty combo with increased death risk

09/7/2005 | USA Today

Many heart attack patients are given a clot-busting drug prior to a planned angioplasty, but the combined treatment could increase a patient's risk of death following the artery-widening procedure, according to a new study. Researchers studying 1,667 patients found that 6% of patients given the clot-busting drug TNKase died within 30 days of their angioplasty, compared with just 3.8% of those who had an angioplasty with no clot-buster.

View Full Article in:

USA Today

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA